(Q36652827)

15 August 2017

1 reference

title

Practical review of oral antihyperglycemic agents for type 2 diabetes mellitus (English)

1 reference

15 August 2017

1 reference

Renee Rae Koski

1

1 reference

15 August 2017

publication date

1 November 2006

1 reference

The Science of Diabetes Self-Management and Care

15 August 2017

published in

1 reference

15 August 2017

volume

32

1 reference

15 August 2017

issue

6

1 reference

15 August 2017

page(s)

869-876

1 reference

Pharmacologic therapy for type 2 diabetes mellitus

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0145721706294260

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0145721706294260

The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0145721706294260

Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0145721706294260

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0145721706294260

Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0145721706294260

Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0145721706294260

A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0145721706294260

Current oral agents for type 2 diabetes. Many options, but which to choose when?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0145721706294260

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0145721706294260

Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0145721706294260

Rational drug design and PPAR agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0145721706294260

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0145721706294260

Hepatotoxicity with thiazolidinediones: is it a class effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0145721706294260

Insulinotropic meglitinide analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0145721706294260

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0145721706294260

Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0145721706294260

Mitiglinide: KAD 1229, S 21403

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0145721706294260

Metformin monotherapy for type 2 diabetes mellitus

21 January 2018

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD002966.PUB3

Identifiers

DOI

10.1177/0145721706294260

1 reference

15 August 2017

1 reference